| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.53 [0.38, 0.74] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | crucial | - |
| deaths (OS) (extension) | 0.68 [0.55, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.71 [0.60, 0.84] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.69 [0.57, 0.84] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 2.07 [1.58, 2.73] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) (extension) | 2.28 [1.74, 3.00] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE leading to death (grade 5) | 0.72 [0.33, 1.58] | | < 1 | | 0% | 1 study (1/-) | 79.3 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.62 [0.28, 1.39] | | < 1 | | 0% | 1 study (1/-) | 87.7 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.26 [0.96, 1.65] | | < 1 | | 0% | 1 study (1/-) | 5.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.56 [0.16, 1.93] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 3.10 [2.12, 4.54] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 5.98 [0.30, 119.72] | | < 1 | | 0% | 1 study (1/-) | 12.4 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.07 [0.01, 0.57] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.49 [0.25, 8.96] | | < 1 | | 0% | 1 study (1/-) | 33.2 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.49 [0.18, 1.31] | | < 1 | | 0% | 1 study (1/-) | 92.2 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 16.13 [0.92, 281.80] | | < 1 | | 0% | 1 study (1/-) | 3.0 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 4.53 [0.97, 21.10] | | < 1 | | 0% | 1 study (1/-) | 2.7 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.66 [0.92, 3.00] | | < 1 | | 0% | 1 study (1/-) | 4.5 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.49 [0.02, 14.79] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Dysphonia TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.46 [0.21, 0.99] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 20.26 [1.18, 348.03] | | < 1 | | 0% | 1 study (1/-) | 2.0 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 1.20 [0.85, 1.68] | | < 1 | | 0% | 1 study (1/-) | 14.7 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 10.01 [0.55, 183.83] | | < 1 | | 0% | 1 study (1/-) | 6.2 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 7.99 [0.42, 151.61] | | < 1 | | 0% | 1 study (1/-) | 8.6 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.99 [0.06, 15.89] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 4.33 [1.88, 10.00] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 5.19 [2.67, 10.10] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.99 [0.06, 15.89] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.56 [0.16, 1.93] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.49 [0.09, 2.71] | | < 1 | | 0% | 1 study (1/-) | 79.1 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.03 [0.00, 0.24] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 1.48 [0.76, 2.89] | | < 1 | | 0% | 1 study (1/-) | 12.7 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.99 [0.14, 7.07] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Proteinuria TRAE (grade 3-4) | 1.84 [0.67, 5.02] | | < 1 | | 0% | 1 study (1/-) | 11.8 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.99 [0.06, 15.89] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.66 [0.39, 6.99] | | < 1 | | 0% | 1 study (1/-) | 24.6 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.33 [0.09, 1.21] | | < 1 | | 0% | 1 study (1/-) | 95.3 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.02 [0.00, 0.35] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 0.99 [0.02, 50.04] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.33 [0.03, 3.17] | | < 1 | | 0% | 1 study (1/-) | 83.0 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 5.00 [0.58, 42.98] | | < 1 | | 0% | 1 study (1/-) | 7.2 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.14 [0.04, 0.46] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 1.32 [0.29, 5.95] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.83 [0.37, 1.88] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.56 [0.16, 1.93] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
| Blood creatinine increased AE (grade 3-4) | 0.66 [0.11, 3.96] | | < 1 | | 0% | 1 study (1/-) | 67.5 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.49 [0.02, 14.79] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.49 [0.04, 5.47] | | < 1 | | 0% | 1 study (1/-) | 71.6 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 4.05 [1.13, 14.45] | | < 1 | | 0% | 1 study (1/-) | 1.6 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 2.03 [1.16, 3.53] | | < 1 | | 0% | 1 study (1/-) | 0.7 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Dyspepsia AE (grade 3-4) | 0.49 [0.02, 14.79] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Dysphonia AE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.39 [0.44, 4.43] | | < 1 | | 0% | 1 study (1/-) | 28.7 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.41 [0.20, 0.81] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 1.99 [0.36, 10.93] | | < 1 | | 0% | 1 study (1/-) | 21.5 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 1.19 [0.85, 1.66] | | < 1 | | 0% | 1 study (1/-) | 15.2 % | NA | not evaluable | | non important | - |
| Hyperthyroidism AE (grade 3-4) | 10.01 [0.55, 183.83] | | < 1 | | 0% | 1 study (1/-) | 6.2 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.99 [0.06, 15.89] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 3.12 [1.51, 6.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 4.86 [2.62, 9.01] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Mucosal inflammation AE (grade 3-4) | 0.49 [0.15, 1.64] | | < 1 | | 0% | 1 study (1/-) | 87.6 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.99 [0.25, 3.99] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.03 [0.00, 0.24] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 1.38 [0.72, 2.67] | | < 1 | | 0% | 1 study (1/-) | 16.8 % | NA | not evaluable | | non important | - |
| Proteinuria AE (grade 3-4) | 2.01 [0.75, 5.40] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 0.99 [0.02, 50.04] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.49 [0.04, 5.47] | | < 1 | | 0% | 1 study (1/-) | 71.6 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 0.33 [0.09, 1.21] | | < 1 | | 0% | 1 study (1/-) | 95.3 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.02 [0.00, 0.31] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.25 [0.03, 2.21] | | < 1 | | 0% | 1 study (1/-) | 89.3 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 13.25 [1.73, 101.75] | | < 1 | | 0% | 1 study (1/-) | 0.7 % | NA | not evaluable | | non important | - |
